Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Dall'Olio FG, Gelsomino F, Conci N, Marcolin L, De Giglio A, Grilli G, Sperandi F, Fontana F, Terracciano M, Fragomeno B, Tober N, Manferrari G, Brocchi S, Golfieri R, Fiorentino M, Ardizzoni A. Dall'Olio FG, et al. Among authors: grilli g. Clin Lung Cancer. 2021 Sep;22(5):423-431. doi: 10.1016/j.cllc.2021.03.005. Epub 2021 Mar 16. Clin Lung Cancer. 2021. PMID: 33849808
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Gelsomino F, Lamberti G, Tiseo M, Rocco D, Pasello G, Cecere FL, Chella A, Grilli G, Mandruzzato M, Tognetto M, Garassino MC, Macerelli M, Novello S, Roila F, Colantonio I, Grossi F, Fiorentino M, Ardizzoni A. Gelsomino F, et al. Among authors: grilli g. Ther Adv Med Oncol. 2020 Jul 20;12:1758835920915983. doi: 10.1177/1758835920915983. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32733604 Free PMC article.
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Ricci AD, Grilli G, Greco A, Montironi R, Ardizzoni A, Massari F. Rizzo A, et al. Among authors: grilli g. Immunotherapy. 2021 Jun;13(9):783-793. doi: 10.2217/imt-2021-0005. Epub 2021 Apr 28. Immunotherapy. 2021. PMID: 33906376
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC.
Dall'Olio FG, Parisi C, Marcolin L, Brocchi S, Caramella C, Conci N, Carpani G, Gelsomino F, Ardizzoni S, Marchese PV, Paccapelo A, Grilli G, Golfieri R, Besse B, Ardizzoni A. Dall'Olio FG, et al. Among authors: grilli g. Ther Adv Med Oncol. 2022 Feb 12;14:17588359211058391. doi: 10.1177/17588359211058391. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35173818 Free PMC article.
161 results